These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7897143)

  • 21. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
    Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN
    Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrocardiographic body surface mapping in patients with ventricular tachycardia. Assessment of utility in the identification of effective pharmacological therapy.
    Mitchell LB; Hubley-Kozey CL; Smith ER; Wyse DG; Duff HJ; Gillis AM; Horacek BM
    Circulation; 1992 Aug; 86(2):383-93. PubMed ID: 1638707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of parasympathetic modulation of the reentrant arrhythmic substrate in the genesis of sustained ventricular tachycardia.
    Kjellgren O; Ip J; Suh K; Gomes JA
    Pacing Clin Electrophysiol; 1994 Jul; 17(7):1276-87. PubMed ID: 7524041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemodynamic and catecholamine response to simulated ventricular tachycardia in man: effect of baseline left ventricular function.
    Kolettis TM; Psarros E; Kyriakides ZS; Katsouras CS; Michalis LK; Sideris DA
    Heart; 2003 Mar; 89(3):306-10. PubMed ID: 12591837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of intravenous quinidine.
    Swerdlow CD; Yu JO; Jacobson E; Mann S; Winkle RA; Griffin JC; Ross DL; Mason JW
    Am J Med; 1983 Jul; 75(1):36-42. PubMed ID: 6859083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Greater quinidine-induced QTc interval prolongation in women.
    Benton RE; Sale M; Flockhart DA; Woosley RL
    Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive prediction of efficacy of type IA antiarrhythmic drugs by the signal-averaged electrocardiogram in patients with coronary artery disease and sustained ventricular tachycardia.
    Hopson JR; Kienzle MG; Aschoff AM; Shirkey DR
    Am J Cardiol; 1993 Aug; 72(3):288-93. PubMed ID: 8342506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute blood pressure effects at the onset of supraventricular and ventricular tachycardia.
    Taneja T; Kadish AH; Parker MA; Goldberger JJ
    Am J Cardiol; 2002 Dec; 90(12):1294-9. PubMed ID: 12480037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'.
    Bozic B; Uzelac TV; Kezic A; Bajcetic M
    Mini Rev Med Chem; 2018; 18(6):468-475. PubMed ID: 28685701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ventricular fibrillation threshold in canine hearts with quinidine induced prolonged QT interval: effects of atrial pacing, isoproterenol, and lignocaine.
    Inoue H; Matsuo H; Mashima S; Sugimoto T; Murao S
    Cardiovasc Res; 1986 May; 20(5):349-57. PubMed ID: 3756976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Quinidine and high-amplification ECG].
    Brembilla-Perrot B; Beurrier D; Jacquemin L; Malak S; Danchin N
    Ann Cardiol Angeiol (Paris); 1997 Jan; 46(1):15-20. PubMed ID: 9092373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrocardiographic correlates of spontaneous termination of ventricular tachycardia in patients with coronary artery disease.
    Duff HJ; Mitchell LB; Gillis AM; Sheldon RS; Chudleigh L; Cassidy P; Chiamvimonvat N; Wyse DG
    Circulation; 1993 Sep; 88(3):1054-62. PubMed ID: 8353867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of electrophysiologic effects of quinidine and amiodarone in sustained ventricular tachyarrhythmias associated with coronary artery disease.
    Pastor A; Almendral JM; Arenal A; Lorca MT; Delcán JL
    Am J Cardiol; 1993 Dec; 72(18):1389-94. PubMed ID: 8256732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.
    Domanski MJ; Sakseena S; Epstein AE; Hallstrom AP; Brodsky MA; Kim S; Lancaster S; Schron E
    J Am Coll Cardiol; 1999 Oct; 34(4):1090-5. PubMed ID: 10520795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of procainamide on the signal-averaged electrocardiogram in relation to the results of programmed ventricular stimulation in patients with sustained monomorphic ventricular tachycardia.
    Kulakowski P; Bashir Y; Heald S; Paul V; Anderson MH; Gibson S; Malik M; Camm AJ
    J Am Coll Cardiol; 1993 May; 21(6):1428-39. PubMed ID: 8473652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of patients with sustained ventricular tachycardia and of survivors of cardiac arrest not inducible by programmed stimulation.
    Andresen D; Steinbeck G; Brüggemann T; Haberl R; Fink L; Schröder R
    Am J Cardiol; 1992 Nov; 70(15):1250-4. PubMed ID: 1442574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Torsades de pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities.
    Horowitz LN; Greenspan AM; Spielman SR; Josephson ME
    Circulation; 1981 May; 63(5):1120-8. PubMed ID: 7471373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.